Table 6.

Association between flavonol intake by serum IL-6 concentrations and colorectal adenoma recurrence among intervention group participants of the PPT (n = 872)

Flavonol* (mg/d)IL-6 (pg/mL)Adenoma recurrence (T4)
NoAdvancedHigh-riskAny
n (%)n (%)OR (95% CI)n (%)OR (95% CI)n (%)OR (95% CI)
Mean (T1,2,3)Baseline (T0)
    Low ≤29.7High >1.90131 (58.0)16 (7.1)1.0038 (16.8)1.0095 (42.0)1.00
Low ≤1.90131 (62.4)20 (9.5)1.57 (0.75-3.27)24 (11.4)0.81 (0.45-1.48)79 (37.6)0.94 (0.63-1.40)
    High >29.7High >1.90128 (61.2)6 (2.9)0.42 (0.15-1.15)15 (7.2)0.47 (0.24-0.93)81 (38.8)0.97 (0.65-1.45)
Low ≤1.90134 (59.0)7 (3.1)0.68 (0.25-1.86)23 (10.1)0.99 (0.52-1.89)93 (41.0)1.30 (0.87-1.95)
Mean (T1,2,3)Trial (T1,3)
    Low ≤29.7High >1.99144 (58.5)20 (8.1)1.0043 (17.5)1.00102 (41.5)1.00
Low ≤1.99118 (62.1)16 (8.4)1.22 (0.58-2.54)19 (10.0)0.65 (0.35-1.20)72 (37.9)0.99 (0.66-1.47)
   High >29.7High >1.99108 (57.1)7 (3.7)0.51 (0.20-1.31)18 (9.5)0.64 (0.33-1.23)81 (42.9)1.19 (0.80-1.79)
Low ≤1.99154 (62.3)6 (2.4)0.40 (0.15-1.07)20 (8.1)0.64 (0.34-1.19)93 (37.7)1.11 (0.75-1.64)
Mean (T1,2,3)Change (T1,3-T0)
    Low ≤29.7High >0.06138 (58.2)22 (9.3)1.0036 (15.2)1.0099 (41.8)1.00
Low ≤0.06124 (62.3)14 (7.0)0.72 (0.35-1.51)26 (13.1)0.78 (0.43-1.40)75 (37.7)0.86 (0.58-1.27)
    High >29.7High >0.06114 (57.6)9 (4.6)0.62 (0.26-1.49)21 (10.6)0.90 (0.47-1.72)84 (42.4)1.20 (0.80-1.80)
Low ≤0.06148 (62.2)4 (1.7)0.19 (0.06-0.58)17 (7.1)0.51 (0.27-0.99)90 (37.8)0.98 (0.67-1.45)
  • *Flavonol intake below or above the median of the mean intake during the first 3 trial years (T1,2,3).

  • IL-6 concentrations below or above the median baseline IL-6 concentration (T0), of the median trial IL-6 concentration (T1,3), and of the median change in IL-6 concentrations from baseline [Change (T1,3-T0)].

  • Multivariate OR and 95% CI models were adjusted for age tertiles (<58, 58-66, >66 y), sex, average BMI (<25, 25.0-29.9, ≥30 kg/m2), current smoking status, and average energy intake (continuous) during the first 3 trial years.